BTK and leukemia: Ibrutinib, and second-generation BTKi’s, such as acalabrutinib and zanubrutinib, form a covalent bond with BTK within its kinase domain at residue C481, causing permanent inactivation of BTK and requiring the leukemia cell to synthesize new enzyme to restore B-cell signaling [2].